Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed360%
terminated120%
active_not_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_1

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272
completedphase_1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334
completedphase_1

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

NCT03099109
completedphase_1

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323
terminatedphase_1

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

NCT03343613

Clinical Trials (5)

Showing 5 of 5 trials
NCT02937272Phase 1

A Study of LY3200882 in Participants With Solid Tumors

Active Not Recruiting
NCT02791334Phase 1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Completed
NCT03099109Phase 1

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Completed
NCT03495323Phase 1

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Completed
NCT03343613Phase 1

A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5